StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Worst year in the stock market since 2008

<< Previous

Bullboard Posts

Next >>

Post by Nailbiter2on Dec 29, 2022 10:07am

213 Views

Post# 35195076

Worst year in the stock market since 2008

L2T can stop crying about tax loss selling.
All signs point to "ain't gonna happen".
So far, insiders are holding tight.

The 2022 Tax-Loss Harvesting Deadline Is Looming: What to Buy With Your Proceeds. Mark the calendar for December 28. That's the last day to sell stocks at a loss for for tax-loss harvesting this year. The last day to trade for a loss is not December 31, because it's the settlement date that counts.